✦ Thorne: $3.8 Billion for SupplementsNarrow moat

Procter & Gamble (PG) — the future bets

P&G is paying $3.8 billion for Thorne, a supplement brand, betting its playbook works in wellness as it did in cold remedies and fibre.

On 4 August 2026 P&G agreed to buy Thorne, which its 10-K describes as a "premium wellness and supplement brand", for $3.8 billion1. It expects the deal to close in the second quarter of fiscal 20272. It is P&G's largest health acquisition since it bought Merck KGaA's over-the-counter business for $3.7 billion in fiscal 20193.

P&G health acquisitions ($bn)3.7Merck KGaA OTC, FY20193.8Thorne, agreed Aug 2026P&G Forms 10-K FY2019 and FY2026
Two similar-sized bets on health.

Thorne would sit in the Health Care segment, whose personal health care brands, Metamucil, Neurobion, Pepto-Bismol and Vicks, make up 6% of P&G's net sales4. Personal health care is already the part of Health Care that is gaining: its share rose 0.6 points in the June 2026 quarter5.

The logic fits P&G's playbook. Supplements are bought repeatedly, used daily and chosen partly on trust, the traits of every category P&G leads. The price is modest against a company worth $339.64 billion6 with $9,942 million of cash7.

The risk is the Gillette pattern in small. P&G already carries $41,276 million of goodwill8, and an acquired brand valued on a growth rate it does not reach gets written down. Health Care's chief executive retired in June 2026 and a successor took over9.

The category Thorne joins has been flat in weight. Personal health care was 6% of P&G's net sales in each of fiscal 2024, 2025 and 202610. The acquisition is P&G's way of adding growth to a category that has held its size but not increased it.

On the evidence, this is a sensible, affordable bet whose success cannot yet be measured. The figure to follow once the deal closes is personal health care's share of net sales, 6% in fiscal 202611; if it does not rise, P&G will have bought a brand without buying growth.

Moat trajectory: Widening

Agreement 4 Aug 2026; close expected Q2 FY2027; personal health care share +0.6pt in Q4.

The number that tests this moat
Reported
Personal Health Care share of net sales, FY2026
6%

The category Thorne would join; no rise after closing would mean the purchase added a brand but not growth.

Source: P&G Form 10-K, FY2026 ↗
References
  1. ReportedOn 4 August 2026 P&G agreed to buy Thorne, which its 10-K describes as a "premium wellness and supplement brand", for $3.8 billion.
    Procter & Gamble Form 10-K for fiscal 2026 (year ended 30 June 2026) - notes: restructuring, goodwill and intangibles, acquisitions and divestitures, subsequent events and commitments. — FY2026 · publ. 4 August 2026 · source ↗
  2. ReportedIt expects the deal to close in the second quarter of fiscal 2027.
    Procter & Gamble Form 10-K for fiscal 2026 (year ended 30 June 2026) - consolidated statements of earnings, cash flows and financial position, debt and dividends. — FY2026 · publ. 4 August 2026 · source ↗
  3. ReportedIt is P&G's largest health acquisition since it bought Merck KGaA's over-the-counter business for $3.7 billion in fiscal 2019.
    Procter & Gamble Form 10-K for fiscal 2019 - the $8.3 billion Shave Care impairment, the Merck KGaA over-the-counter acquisition, five-year financial summary, segment shares, Walmart and top-ten customers. — FY2019 · publ. August 2019 · source ↗
  4. ReportedThorne would sit in the Health Care segment, whose personal health care brands, Metamucil, Neurobion, Pepto-Bismol and Vicks, make up 6% of P&G's net sales.
    Procter & Gamble Form 10-K for fiscal 2026 (year ended 30 June 2026) - Item 7 MD&A and segment note: segment contents, operating segments and shares of net sales and net earnings. — FY2026 · publ. 4 August 2026 · source ↗
  5. ReportedPersonal health care is already the part of Health Care that is gaining: its share rose 0.6 points in the June 2026 quarter.
    Procter & Gamble fourth-quarter fiscal 2026 earnings slides, Form 8-K exhibit 99.1 - organic sales and core EPS history, share results and fiscal 2027 guidance assumptions. — Q4 FY2026 · publ. 29 July 2026 · source ↗
  6. ReportedThe price is modest against a company worth $339.64 billion with $9,942 million of cash.
    Procter & Gamble (PG) market data - $146.23 at the close on 25 September 2026, market cap $339.64B, 52-week range 137.62-167.25, analyst target $160.61. — September 2026 · publ. 25 September 2026 · source ↗
  7. ReportedThe price is modest against a company worth $339.64 billion with $9,942 million of cash.
    Procter & Gamble Form 10-K for fiscal 2026 (year ended 30 June 2026) - consolidated statements of earnings, cash flows and financial position, debt and dividends. — FY2026 · publ. 4 August 2026 · source ↗
  8. ReportedP&G already carries $41,276 million of goodwill, and an acquired brand valued on a growth rate it does not reach gets written down.
    Procter & Gamble Form 10-K for fiscal 2026 (year ended 30 June 2026) - notes: restructuring, goodwill and intangibles, acquisitions and divestitures, subsequent events and commitments. — FY2026 · publ. 4 August 2026 · source ↗
  9. ReportedHealth Care's chief executive retired in June 2026 and a successor took over.
    Procter & Gamble Form 8-K of 15 December 2025 - retirement of the Chief Executive Officer of Health Care effective 30 June 2026. — December 2025 · publ. 15 December 2025 · source ↗
  10. ReportedPersonal health care was 6% of P&G's net sales in each of fiscal 2024, 2025 and 2026.
    Procter & Gamble Form 10-K for fiscal 2026 (year ended 30 June 2026) - Item 7 MD&A and segment note: segment contents, operating segments and shares of net sales and net earnings. — FY2026 · publ. 4 August 2026 · source ↗
  11. ReportedThe figure to follow once the deal closes is personal health care's share of net sales, 6% in fiscal 2026; if it does not rise, P&G will have bought a brand without buying growth.
    Procter & Gamble Form 10-K for fiscal 2026 (year ended 30 June 2026) - Item 7 MD&A and segment note: segment contents, operating segments and shares of net sales and net earnings. — FY2026 · publ. 4 August 2026 · source ↗
Sources
Generated September 26, 2026